An oral dosage form comprising a compound of formula (I): ** Formula ** or a pharmaceutically acceptable salt thereof, wherein the oral dosage form consists of approximately 9% by weight of the compound of formula (I) , approximately 51% by weight of hydroxypropylmethylcellulose, approximately 34% by weight of mannitol, approximately 5% by weight of croscarmellose sodium and approximately 1% by weight of calcium stearate, or in which the dosage form consists of approximately 7% in weight of the compound of formula (I), approximately 63% by weight of hydroxypropylmethylcellulose, approximately 24% by weight of mannitol, approximately 5% by weight of croscarmellose sodium and approximately 1% by weight of calcium stearate, or in which The dosage form consists of approximately 9% by weight of the compound of formula (I), approximately 51% by weight of polyvinylpyrrolidone-vinyl acetate copolymer, approximately 34% by weight of ma nitol, about 5% by weight of croscarmellose sodium and about 1% by weight of calcium stearate.Una forma de dosificación oral que comprende un compuesto de fórmula (I):**Fórmula** o una sal farmacéuticamente aceptable del mismo, en la que la forma de dosificación oral consiste en aproximadamente 9% en peso del compuesto de fórmula (I), aproximadamente 51% en peso de hidroxipropilmetilcelulosa, aproximadamente 34% en peso de manitol, aproximadamente 5% en peso de croscarmelosa sódica y aproximadamente 1% en peso de estearato de calcio, o en la que la forma de dosificación consiste en aproximadamente 7% en peso del compuesto de fórmula (I), aproximadamente 63% en peso de hidroxipropilmetilcelulosa, aproximadamente 24% en peso de manitol, aproximadamente 5% en peso de croscarmelosa sódica y aproximadamente 1% en peso en peso de estearato de calcio, o en la que la forma de dosificación consiste en aproximadamente 9% en peso del compuesto de fórmula (I), aproximadamente 51% en peso de copolímero de polivinilpirrolidona-acetato de vinilo, aproximadam
